Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 04.05.2025 1 AJR Am J Roentgenol 1 Am J Pathol 1 Am J Respir Cell Mol Biol 1 Ann Oncol 1 Ann Surg Oncol 1 Ann Thorac Surg 5 Anticancer Res 1 Arch Bronconeumol 7 BMC Cancer 1 Cancer 3 Cancer Res 2 Cancer Sci 2 Clin Cancer Res 7 Clin Lung Cancer 3 Eur J Cancer 1 Eur J Cardiothorac Surg 2 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Surg Oncol 1 J Thorac Cardiovasc Surg 4 Lung Cancer 1 Lung Cancer (Auckl) 2 Mol Cancer Ther 1 N Engl J Med 1 Oncogene 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. HAMMER MM
   Scrutinizing the Benefits of Artificial Intelligence Nodule Detection in Lung Cancer Screening.
   AJR Am J Roentgenol. 2025 Apr 30. doi: 10.2214/AJR.25.33134.
   PubMed        
   
   

   
   Am J Pathol

2. GERTYCH A, Zurek N, Piaseczna N, Szkaradnik K, et al
   Tumor Cellularity Assessment Using Artificial Intelligence Trained on Immunohistochemistry-Restained Slides Improves Selection of Lung Adenocarcinoma Samples for Molecular Testing.
   Am J Pathol. 2025;195:907-922.
   PubMed         Abstract available
   
   

   
   Am J Respir Cell Mol Biol

3. TREFIER A, Tousson-Abouelazm N, Yamani L, Ibrahim S, et al
   Enhanced Galphaq Signaling in TSC2-Deficient Cells Is Required for Their Neoplastic Behavior.
   Am J Respir Cell Mol Biol. 2025;72:578-590.
   PubMed         Abstract available
   
   

   
   Ann Oncol

4. FELIP E, Popat S, Dafni U, Ribi K, et al
   A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.
   Ann Oncol. 2025;36:548-560.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. NAEEM W, Khan AA, Adebayo OW, Ansari M, et al
   Difficult Decisions in the Multidisciplinary Treatment of Resectable Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Apr 28. doi: 10.1245/s10434-025-17345.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

6. WOODARD GA, Grau-Sepulveda M, Onaitis MW, Udelsman BV, et al
   Lobectomy vs Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation.
   Ann Thorac Surg. 2025;119:1071-1081.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. TSUKAMOTO YO, Ohtsuka T, Yamauchi Y, Mun M, et al
   Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer.
   Anticancer Res. 2025;45:2071-2078.
   PubMed         Abstract available
   
   
8. DICKE J, Hero L, Kuhl S, Goldbrunner R, et al
   Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.
   Anticancer Res. 2025;45:1807-1812.
   PubMed         Abstract available
   
   
9. ASANO Y, Han Q, Mizuta K, Kang BM, et al
   Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis Lung Carcinoma Cells But Not Normal Fibroblasts.
   Anticancer Res. 2025;45:1871-1876.
   PubMed         Abstract available
   
   
10. PROBST E, Idel C, Fleckner J, Plotze-Martin K, et al
    Elevated PD-L1 Expression on Circulating Classical Monocytes Upon Checkpoint Inhibitor Therapy Is Associated With Increased Plasma Interleukin 5 in Patients With Lung Cancer.
    Anticancer Res. 2025;45:1915-1925.
    PubMed         Abstract available
    
    
11. HWANG HH, Yoo JS, Je JH, Lee HC, et al
    SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by Inhibiting the Receptor Tyrosine Kinase-related Pathway.
    Anticancer Res. 2025;45:1981-1995.
    PubMed         Abstract available
    
    

    
    Arch Bronconeumol

12. DIAZ-GARCIA E, Alfaro E, Perez-Moreno P, Lopez-Fernandez C, et al
    Immune Checkpoint Biomarkers Galectin-9 and TIM-3 Predict Melanoma and Lung Cancer Mortality in Obstructive Sleep Apnoea.
    Arch Bronconeumol. 2025 Apr 2:S0300-2896(25)00116.
    PubMed         Abstract available
    
    

    
    BMC Cancer

13. ZHU Q, Hu H, OuYang LY, Yang R, et al
    The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer.
    BMC Cancer. 2025;25:799.
    PubMed         Abstract available
    
    
14. WANG Y, Ma X, Ma J, Li J, et al
    Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer.
    BMC Cancer. 2025;25:791.
    PubMed         Abstract available
    
    
15. OU G, Gao T, Hu S, Zhang S, et al
    Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma.
    BMC Cancer. 2025;25:783.
    PubMed         Abstract available
    
    
16. LI S, Huang Z, Zhong X, Zhou Y, et al
    The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database.
    BMC Cancer. 2025;25:767.
    PubMed         Abstract available
    
    
17. HAJIKARIMLOO B, Mohammadzadeh I, Tos SM, Habibi MA, et al
    Machine learning in prediction of epidermal growth factor receptor status in non-small cell lung cancer brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:818.
    PubMed         Abstract available
    
    
18. KUANG S, Xiao S, Zhou J, Liu L, et al
    Combined effect of areca nut, cigarettes, alcohol and SNPs in glycosyltransferase family genes on lung cancer development in Hainan, China.
    BMC Cancer. 2025;25:814.
    PubMed         Abstract available
    
    
19. LIAO J, Hu X, Wei X, Dai W, et al
    Sex-related differences in postoperative patient-reported outcomes among lung cancer patients: a multicenter cohort study.
    BMC Cancer. 2025;25:800.
    PubMed         Abstract available
    
    

    
    Cancer

20. THOMAS QD, Vendrell JA, Khellaf L, Cavaillon S, et al
    Artificial intelligence-driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer.
    Cancer. 2025;131:e35882.
    PubMed         Abstract available
    
    

    
    Cancer Res

21. HAN J, Du J, Li X, Zhou Q, et al
    The Glycosyltransferase XYLT1 Activates NF-kappaB Signaling to Promote Metastasis of Early-Stage Lung Adenocarcinoma.
    Cancer Res. 2025;85:1628-1643.
    PubMed         Abstract available
    
    
22. PAPARGYRIOU A, Reichert M
    The Biology in the Pattern: Metastatic Organotropism and Clinical Outcome Depend on DNA Damage Response and Immune Interactions in Pancreatic Cancer.
    Cancer Res. 2025;85:1571-1573.
    PubMed         Abstract available
    
    
23. CAI L, Wu F, Zhou Q, Gao Y, et al
    The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models.
    Cancer Res. 2025 Apr 29:OF1-OF15. doi: 10.1158/0008-5472.CAN-24-1607.
    PubMed         Abstract available
    
    

    
    Cancer Sci

24. MONIWA K, Tokita S, Sumi T, Saijo H, et al
    Loss of Tapasin in Tumors Potentiates T-Cell Recognition and Anti-Tumor Effects of Immune Checkpoint Blockade.
    Cancer Sci. 2025;116:1203-1213.
    PubMed         Abstract available
    
    
25. MIYASHITA Y, Tajima K, Izumi K, Matsumoto N, et al
    Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors.
    Cancer Sci. 2025;116:1392-1404.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

26. HIRSCH FR
    Antibody Drug Conjugates in Non-Small Cell Lung Cancer: Where is the Target and the Biomarker?
    Clin Cancer Res. 2025 Apr 28. doi: 10.1158/1078-0432.CCR-25-0839.
    PubMed         Abstract available
    
    
27. ZHANG J, Jin Y, Lin H, Deng J, et al
    Amplification of extrachromosomal MYC paralogs shapes immunosuppressive tumor microenvironment in small cell lung cancer.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3399.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

28. BRUNELLI A, Hoffman R, Wotton R, Baijal S, et al
    Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England.
    Clin Lung Cancer. 2025;26:253-261.
    PubMed         Abstract available
    
    
29. PHAM D, Park JA, Wang H, Subramanian M, et al
    Computer Assisted Nodule Analysis and Risk Yield is Associated With Occult Lymph Node Status in Clinical Stage I-IIA Lung Adenocarcinoma Undergoing Resection.
    Clin Lung Cancer. 2025;26:e142-e149.
    PubMed         Abstract available
    
    
30. BOLTE FJ, Dougherty SC, Danos AO, Lynch AC, et al
    Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases.
    Clin Lung Cancer. 2025 Mar 26:S1525-7304(25)00052.
    PubMed         Abstract available
    
    
31. RIOS-GARCIA E, Guijosa A, Caballe-Perez E, Davila-Dupont D, et al
    Elucidating the Role of EGFR(L858R) in Brain Metastasis Among Patients With Advanced NSCLC Undergoing TKI Therapy.
    Clin Lung Cancer. 2025;26:e199-e206.
    PubMed         Abstract available
    
    
32. SOLIMAN MM, Gershon B, Ra DS, Escalon JG, et al
    Imaging Findings Related to Lung Tract Sealant Use in Percutaneous CT-guided Lung Biopsy.
    Clin Lung Cancer. 2025;26:236-243.
    PubMed         Abstract available
    
    
33. TAJE R, Ambrogi V, Tacconi F, Gallina FT, et al
    Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung Adenocarcinoma.
    Clin Lung Cancer. 2025;26:210-220.
    PubMed         Abstract available
    
    
34. TAKAMORI S, Endo M, Hamada A, Ohara S, et al
    Prognostic Analysis of Pathological Stage I Lung Adenocarcinoma Harboring Major EGFR Mutations.
    Clin Lung Cancer. 2025;26:e172-e180.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

35. AGRAWAL M, Surendran AK, Biswas R
    Letter Re: Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
    Eur J Cancer. 2025 Apr 23:115442. doi: 10.1016/j.ejca.2025.115442.
    PubMed        
    
    
36. MONACA F, Gomez-Randulfe I, Parreira AS, Longo V, et al
    Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.
    Eur J Cancer. 2025;221:115435.
    PubMed         Abstract available
    
    
37. AIGNER C, Baldes N, Begic M, Doerr F, et al
    Current perspective on resectability in stage III locally advanced NSCLC - The thoracic surgeons' view.
    Eur J Cancer. 2025;221:115426.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

38. TAKENAKA H, Nakagawa K, Yotsukura M, Yoshida Y, et al
    Prognosis of adenocarcinoma with innumerable pure ground-glass nodules and/or part-solid nodules.
    Eur J Cardiothorac Surg. 2025;67:ezaf130.
    PubMed         Abstract available
    
    

    
    Int J Cancer

39. TSURUDA KM, Hektoen HH, Aamelfot C, Andreassen BK, et al
    Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer.
    Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35445.
    PubMed         Abstract available
    
    
40. XIE Y, Fang H, Cheng W, Xu T, et al
    Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.
    Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35460.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

41. ALFAIFI SA, Louie AV, Siva S, Guckenberger M, et al
    International Patterns of Practice for Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Are We All in Sync?: Global patterns of practice for SABR for early-stage NSCLC.
    Int J Radiat Oncol Biol Phys. 2025 Apr 29:S0360-3016(25)00390.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

42. DEREK DE-RUI H, Yang JC
    Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Apr 25:JCO2500625. doi: 10.1200/JCO-25-00625.
    PubMed        
    
    

    
    J Surg Oncol

43. DRIGOTAS C, Loftus AW, Ammori JB, Rothermel LD, et al
    Perfusion Strategies for Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma.
    J Surg Oncol. 2025;131:310-315.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

44. EISENBERG MA, Werner R, Ries S, Hofstetter WL, et al
    Extent of Resection in Surgically Resected Stage IV Non-Small-Cell Lung Cancer: Results from Two Tertiary Referral Centers.
    J Thorac Cardiovasc Surg. 2025 Apr 23:S0022-5223(25)00327.
    PubMed         Abstract available
    
    

    
    Lung Cancer

45. DHAEYER S, Missault E, Surmont V, Vermaelen K, et al
    Outcome of temozolomide in relapsed small cell lung cancer: A retrospective single center analysis.
    Lung Cancer. 2025;203:108539.
    PubMed         Abstract available
    
    
46. CHO BC, Hayashi H, Lee JS, Lee SH, et al
    Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
    Lung Cancer. 2025;204:108496.
    PubMed         Abstract available
    
    
47. LEE JH, Cha S, Ko EJ, Kim W, et al
    Clinical effect of pulmonary rehabilitation during radiotherapy in lung cancer: A randomized controlled trial.
    Lung Cancer. 2025;204:108546.
    PubMed         Abstract available
    
    
48. LINTAS C, Petti R, Colella G, Cassano I, et al
    Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis.
    Lung Cancer. 2025;204:108560.
    PubMed         Abstract available
    
    

    
    Lung Cancer (Auckl)

49. DAO TV, Dinh VL, Doan TV, Phuong TL, et al
    Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.
    Lung Cancer (Auckl). 2025;16:39-49.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

50. DOMINGUEZ-VIGIL IG, Banik K, Baro M, Contessa JN, et al
    PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity.
    Mol Cancer Ther. 2025 Apr 29. doi: 10.1158/1535-7163.MCT-24-0978.
    PubMed         Abstract available
    
    
51. YUAN R, McGeehan A, Zhou S, Cheng C, et al
    The anti-FRalpha antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy in non-small cell lung cancer preclinical models and induces immunogenic cell death.
    Mol Cancer Ther. 2025 Apr 28. doi: 10.1158/1535-7163.MCT-24-0649.
    PubMed         Abstract available
    
    

    
    N Engl J Med

52. HEYMACH JV, Ruiter G, Ahn MJ, Girard N, et al
    Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2025 Apr 28. doi: 10.1056/NEJMoa2503704.
    PubMed         Abstract available
    
    

    
    Oncogene

53. LIU X, Cui Y, Gong J, Yu X, et al
    SETD5 facilitates stemness and represses ferroptosis via m6A-mediating PKM2 stabilization in non-small cell lung cancer.
    Oncogene. 2025 Apr 30. doi: 10.1038/s41388-025-03426.
    PubMed         Abstract available
    
    

    
    PLoS One

54. MALIK V, Mittal R, Gupta D, Juneja S, et al
    Optimizing chemotherapeutic targets in non-small cell lung cancer with transfer learning for precision medicine.
    PLoS One. 2025;20:e0319499.
    PubMed         Abstract available
    
    
55. YU W, Long L, Hou Q, Yi B, et al
    Development of a nomogram for overall survival prediction in primary upper lobe lung cancer patients: A SEER population-based analysis.
    PLoS One. 2025;20:e0321955.
    PubMed         Abstract available
    
    
56. MOUSAVI SF, Masoudi S, Rezaei N, Pourghazi F, et al
    Survival assessment and pre-diagnostic risk factors for lung cancer incidence: Insights from the Golestan Cohort Study.
    PLoS One. 2025;20:e0320931.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.